Cidara Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Cidara Therapeutics's estimated annual revenue is currently $15.2M per year.
- Cidara Therapeutics's estimated revenue per employee is $155,000
- Cidara Therapeutics's total funding is $156.1M.
Employee Data
- Cidara Therapeutics has 98 Employees.
- Cidara Therapeutics grew their employee count by -4% last year.
Cidara Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Program and Alliance Management | Reveal Email/Phone |
2 | VP Clinical Pharmacology & Early Development | Reveal Email/Phone |
3 | VP, Quality | Reveal Email/Phone |
4 | SVP, People and Culture | Reveal Email/Phone |
5 | SVP Clinical Operations | Reveal Email/Phone |
6 | SVP, Regulatory Affairs and Quality Assurance | Reveal Email/Phone |
7 | VP Technical Operations | Reveal Email/Phone |
8 | Controller | Reveal Email/Phone |
9 | SVP Translational R&D | Reveal Email/Phone |
10 | SVP, Translational Research & Development | Reveal Email/Phone |
Cidara Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Cidara Therapeutics?
Cidara Therapeutics is developing innovative therapies to treat life-threatening illnesses exacerbated by deficiencies of the human immune system. Our initial focus is on devastating fungal infections that often complicate cancer and transplant treatments. Such infections can lead to mortality rates exceeding 50%.
keywords:N/A
$156.1M
Total Funding
98
Number of Employees
$15.2M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cidara Therapeutics News
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Recommendation of Buy from Analysts. Posted by admin on Apr 27th, 2022.
Mundipharma and Cidara Therapeutics Announce First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of...
Cidara is developing a new generation of immunotherapeutic antivirals from its Cloudbreak platform that couple potent antivirals to a human...
Cidara Therapeutics, Inc. (Nasdaq:CDTX), a San Diego, CA-based biotechnology company, entered into an agreement for a $20m credit facility with Square 1 Bank, a division of Pacific Western Bank. Proceeds from the facility will provide working capital to support the company’s CD101 and CD201 pro ...
Cidara Therapeutics Inc. has filed to raise up to $69 million in an IPO, the San Diego biotech disclosed in a registration statement filed recently. The biotechnology company is developing anti-infectives and immunotherapies to treat fungal and other infections. Cidara is making a quick bet th ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $27M | 98 | -7% | $19.5M |
#2 | $34.6M | 98 | 2% | N/A |
#3 | $15M | 98 | -16% | $190.9M |
#4 | $16M | 98 | 5% | N/A |
#5 | $14.7M | 98 | 8% | N/A |